Mylan Inc. has announced that its Mylan Institutional business,  a new customer-focused business providing a differentiated basket of pharmaceutical products and services to institutional customers, has   launched Mesna injection, 100 mg/mL, packaged in 1,000 mg/10mL multiple-dose vials.

This product, which has faced recent shortages in the US, is the generic version of Baxter Healthcare Corporation's Mesnex injection and is indicated as a prophylactic agent in reducing the incidence of ifosfamide-indused hemorrhagic cystitis.

Mesna injection, 100 mg/mL, had US sales of approximately $11.7 million for the 12 months ending December 31, 2011, according to IMS Health. Mylan has begun shipping its generic version, which has been approved by the US Food and Drug Administration (FDA), presented in 10-vial packs.

Currently, Mylan has 173 ANDAs pending FDA approval representing $100.2 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $26.9 billion in annual brand sales, for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories.